Skip to the main content

Review article

Kidney Transplantation in High Immunological Risk Recipients

Bojana Maksimović


Full text: croatian pdf 87 Kb

versions

page 213-218

downloads: 41

cite

Full text: english pdf 87 Kb

versions

page 213-213

downloads: 25

cite


Abstract

HLA (Human Leucocyte Antigen) sensitization is a significant barrier to successful kidney transplantation. It often leads to prolonged waiting time on transplant lists and significantly increased morbidity and mortality. Over the last decade new technologies of HLA antibody identification have emerged, as well as several immunomodulatory therapies allowing for increased access to kidney transplantation for the immunologically disadvantaged group of HLA sensitized end-stage kidney disease patients. Also, a different allocation program was introduced in order to prioritize these groups of patients. Still there is an unmet need for more efficient and safer therapies to avoid HLA sensitization. The collaboration of transplant physicians, immunologists, and pharmaceutical industries is crucial to delineate a path forward to improve access to kidney transplantation.

Keywords

kidney transplantation; HLA sensitization; HLA antibodies

Hrčak ID:

315860

URI

https://hrcak.srce.hr/315860

Publication date:

9.4.2024.

Article data in other languages: croatian

Visits: 136 *